Suppliers and packagers for TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED)

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660	NDA	Vertex Pharmaceuticals Incorporated	51167-445-01	4 PACKAGE in 1 CARTON (51167-445-01) / 1 KIT in 1 PACKAGE * 1 GRANULE in 1 PACKET (51167-545-07) * 1 GRANULE in 1 PACKET (51167-645-07)	2023-04-26
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660	NDA	Vertex Pharmaceuticals Incorporated	51167-446-01	4 PACKAGE in 1 CARTON (51167-446-01) / 1 KIT in 1 PACKAGE * 1 GRANULE in 1 PACKET (51167-746-07) * 1 GRANULE in 1 PACKET (51167-846-07)	2023-04-26
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273	NDA	Vertex Pharmaceuticals Incorporated	51167-106-02	4 BLISTER PACK in 1 CARTON (51167-106-02) / 1 KIT in 1 BLISTER PACK * 14 TABLET, FILM COATED in 1 BLISTER PACK (51167-206-14) * 7 TABLET, FILM COATED in 1 BLISTER PACK (51167-306-07)	2021-06-08
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273	NDA	Vertex Pharmaceuticals Incorporated	51167-331-01	4 BLISTER PACK in 1 CARTON (51167-331-01) / 1 KIT in 1 BLISTER PACK * 14 TABLET, FILM COATED in 1 BLISTER PACK (51167-431-14) * 7 TABLET, FILM COATED in 1 BLISTER PACK (51167-531-07)	2019-10-21

TRIKAFTA (COPACKAGED) Drug Substance Manufacturing Supply Chain Analysis

Last updated: February 19, 2026

TRIKAFTA (Elexacaftor/tezacaftor/ivacaftor and ivacaftor) is a co-packaged oral therapy for cystic fibrosis (CF). The drug substance manufacturing for TRIKAFTA involves multiple active pharmaceutical ingredients (APIs) requiring distinct synthetic pathways. Vertex Pharmaceuticals is the primary innovator and marketer. The supply chain for these APIs is complex, involving specialized chemical manufacturers.

What are the Key Active Pharmaceutical Ingredients in TRIKAFTA?

TRIKAFTA is comprised of four active molecules: elexacaftor, tezacaftor, ivacaftor, and a second instance of ivacaftor. Elexacaftor, tezacaftor, and ivacaftor are the primary therapeutic agents, with ivacaftor also included at a different dosage.

• Elexacaftor: A potentiator that increases the function of the F508del-CFTR protein.
• Tezacaftor: A corrector that helps move the F508del-CFTR protein to the cell surface.
• Ivacaftor: A potentiator that increases the function of CFTR protein with certain gating mutations.

Who are the Identified Suppliers of TRIKAFTA's Active Pharmaceutical Ingredients?

Identifying direct suppliers of finished drug substance for a proprietary drug like TRIKAFTA is challenging due to confidentiality agreements common in the pharmaceutical industry. However, patent literature and public domain information can indicate potential manufacturing sites or companies involved in the synthesis of the constituent APIs or their key intermediates. Vertex Pharmaceuticals, the originator, is understood to manage and potentially operate some of its own manufacturing or contract with specific CDMOs (Contract Development and Manufacturing Organizations).

Based on patent filings and typical industry practices for complex small molecules, the following entities are plausible contributors or have been associated with the synthesis of related compounds:

• Vertex Pharmaceuticals: As the innovator, Vertex likely oversees the manufacturing process, potentially through wholly-owned subsidiaries or dedicated internal manufacturing facilities for critical steps. They hold numerous patents covering the synthesis of these molecules.
• Contract Manufacturing Organizations (CMOs) / Contract Development and Manufacturing Organizations (CDMOs): It is standard practice for pharmaceutical companies to outsource API manufacturing to specialized CMOs/CDMOs. These organizations possess the expertise and infrastructure for multi-step organic synthesis. While specific contracts are not publicly disclosed, companies with a strong track record in complex API synthesis are likely candidates. Examples of such companies globally include:
  • Lonza Group
  • Catalent
  • Thermo Fisher Scientific (Patheon)
  • WuXi AppTec
  • Samsung Biologics
  • ASCAYA (formerly Alcami)

These organizations often have multiple sites capable of producing APIs under strict Good Manufacturing Practices (GMP).

What are the Chemical Synthesis Challenges for TRIKAFTA's APIs?

The synthesis of elexacaftor, tezacaftor, and ivacaftor is complex, involving multiple chiral centers and specific regiochemical control. This complexity necessitates advanced synthetic methodologies and rigorous quality control.

• Elexacaftor: The synthesis involves several steps, including cyclization reactions and the introduction of specific functional groups. Patent literature suggests routes that require precise control over stereochemistry. For example, U.S. Patent 10,676,472 B2 describes synthetic routes for elexacaftor, highlighting the need for specialized reagents and reaction conditions. The molecular formula is C27H29F3N4O5S, and its molecular weight is 582.61 g/mol.
• Tezacaftor: The synthesis of tezacaftor (VX-661) is also multi-step, involving heterocyclic chemistry and chiral separations or asymmetric synthesis. U.S. Patent 9,573,910 B2 details synthetic approaches. The molecular formula is C21H22F2N6O3S, and its molecular weight is 476.50 g/mol.
• Ivacaftor: The synthesis of ivacaftor (VX-770) involves the construction of a benzopyran core and subsequent functionalization. U.S. Patent 7,943,618 B2 describes its synthesis. The molecular formula is C21H24N2O3, and its molecular weight is 352.43 g/mol.

The co-packaging of these distinct APIs requires parallel manufacturing streams, each optimized for yield, purity, and scalability.

What are the Patent Landscape Considerations for TRIKAFTA's APIs?

Vertex Pharmaceuticals holds a strong portfolio of patents covering the composition of matter, methods of synthesis, and therapeutic uses of elexacaftor, tezacaftor, and ivacaftor, as well as their combinations.

• Composition of Matter Patents: These patents protect the chemical structure of the APIs themselves. Key patents for the individual components and the combination are fundamental to Vertex's market exclusivity.
• Process Patents: These patents cover specific methods of synthesizing the APIs. For complex molecules, innovative and efficient synthetic routes are often patented, providing an additional layer of protection.
  • U.S. Patent 10,676,472 B2 (Elexacaftor synthesis)
  • U.S. Patent 9,573,910 B2 (Tezacaftor synthesis)
  • U.S. Patent 7,943,618 B2 (Ivacaftor synthesis)
• Formulation and Co-packaging Patents: Patents also exist for the specific co-packaged formulation of TRIKAFTA, detailing how the different pills are combined for patient convenience and stability.
• Exclusivity Periods: The duration of patent protection and any granted exclusivities (e.g., New Chemical Entity exclusivity) are critical for understanding the market entry timeline for potential generic competitors. The primary patents for these molecules began to expire around 2030, but patent extensions and additional later-expiring patents, particularly for manufacturing processes and specific crystalline forms, can influence the actual generic entry date.

The intricate patent landscape suggests that any generic manufacturer seeking to enter the market will face significant legal and technical hurdles in developing non-infringing synthetic routes and formulations.

What are the Regulatory and Quality Control Requirements for TRIKAFTA's APIs?

Manufacturing APIs for a complex, multi-component drug like TRIKAFTA necessitates adherence to stringent global regulatory standards, primarily Good Manufacturing Practices (GMP).

• GMP Compliance: All manufacturing sites involved in API production must comply with FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and other relevant health authority regulations. This includes:
  • Robust quality management systems.
  • Validated manufacturing processes.
  • Strict control over raw materials and intermediates.
  • Comprehensive analytical testing for identity, purity, potency, and impurities.
• Impurity Profiling: The identification and control of process-related impurities and degradation products are critical. Regulatory agencies require detailed impurity profiles and qualified analytical methods for their detection and quantification.
• Stability Testing: APIs must undergo rigorous stability testing to determine their shelf life under various storage conditions.
• Supply Chain Transparency: Regulatory bodies increasingly demand transparency and traceability throughout the pharmaceutical supply chain. Manufacturers must have a thorough understanding of their own suppliers and subcontractors.

The complexity of TRIKAFTA's APIs means that specialized analytical techniques, such as High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR) spectroscopy, are essential for quality control.

What is the Supply Chain Risk Profile for TRIKAFTA?

The supply chain for TRIKAFTA carries several inherent risks due to its complexity and reliance on specialized manufacturing.

• Geopolitical Risks: Reliance on manufacturing sites in specific geographic regions can expose the supply chain to geopolitical instability, trade disputes, or natural disasters.
• Single-Source Dependency: If critical intermediates or specific manufacturing steps are sourced from a single supplier, any disruption at that supplier can have a significant impact on TRIKAFTA availability. This is particularly true for proprietary synthesis routes.
• Intellectual Property Challenges: While Vertex holds strong patents, the threat of patent litigation or the development of non-infringing processes by competitors poses a long-term risk.
• Quality and Compliance Issues: Any lapse in GMP compliance at any manufacturing site can lead to batch rejections, recalls, and regulatory scrutiny, impacting supply continuity.
• Raw Material Sourcing: The availability and quality of precursor chemicals and reagents used in the multi-step syntheses can be a source of vulnerability.

Vertex Pharmaceuticals likely employs risk mitigation strategies such as dual sourcing for critical raw materials, qualification of multiple CMOs for key manufacturing steps where feasible, and robust supply chain monitoring.

What are the Market Implications for TRIKAFTA's Suppliers?

The suppliers engaged in the TRIKAFTA supply chain, whether for API manufacturing or intermediate synthesis, operate in a high-value, high-demand segment of the pharmaceutical market.

• High Barrier to Entry: The technical expertise required for the synthesis of these complex molecules, coupled with the stringent regulatory and IP landscape, creates a high barrier to entry for new suppliers.
• Long-Term Contracts: Successful suppliers typically secure long-term supply agreements with the innovator pharmaceutical company, providing revenue stability.
• Investment in Capabilities: To be a competitive supplier for drugs like TRIKAFTA, organizations must make significant investments in specialized equipment, R&D for process optimization, and robust quality systems.
• Competitive Landscape: While Vertex controls the final product, the upstream supply of APIs and advanced intermediates involves a competitive group of global CDMOs, each vying for lucrative contracts.

The successful manufacturing of TRIKAFTA's APIs demonstrates a high level of chemical synthesis capability and operational excellence.

Key Takeaways

• TRIKAFTA comprises four active molecules: elexacaftor, tezacaftor, and ivacaftor (twice).
• Vertex Pharmaceuticals is the innovator, managing a complex supply chain likely involving internal manufacturing and specialized CDMOs for API synthesis.
• The synthesis of elexacaftor, tezacaftor, and ivacaftor presents significant chemical complexity, requiring advanced synthetic routes and strict stereochemical control.
• Vertex Pharmaceuticals possesses a robust patent portfolio covering composition of matter, synthesis processes, and formulations, influencing market exclusivity.
• All API manufacturing must adhere to stringent global GMP regulations, with rigorous quality control for impurities and product stability.
• Supply chain risks include geopolitical factors, single-source dependency, IP challenges, and quality compliance issues.
• Suppliers for TRIKAFTA's APIs operate in a high-value market segment characterized by high technical and regulatory barriers to entry.

Frequently Asked Questions

1. Which specific Contract Development and Manufacturing Organizations (CDMOs) are confirmed manufacturers of TRIKAFTA's APIs? Confirmed contracts between Vertex Pharmaceuticals and specific CDMOs for TRIKAFTA API manufacturing are not publicly disclosed due to confidentiality agreements.
2. What is the estimated annual production volume for TRIKAFTA's APIs? Annual production volumes are proprietary information linked to Vertex Pharmaceuticals' sales forecasts and are not publicly available.
3. Are there any known generic competitors actively developing non-infringing synthesis routes for TRIKAFTA's APIs? While patent challenges and Paragraph IV filings are common for successful drugs, specific details on generic competitors' development activities for TRIKAFTA are not publicly confirmed until legal actions are taken.
4. What is the typical lead time for a CDMO to scale up production for a complex API like those in TRIKAFTA? Lead times can range from 12 to 24 months or more, depending on process complexity, technology transfer requirements, and regulatory validation.
5. How does the co-packaging of TRIKAFTA affect its API supply chain compared to a single-API drug? Co-packaging requires parallel, independent manufacturing streams for each distinct API, increasing overall supply chain complexity and the number of critical control points that must be managed.

Citations

[1] Elexacaftor. (n.d.). Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Elexacaftor

[2] Tezacaftor. (n.d.). Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Tezacaftor

[3] Ivacaftor. (n.d.). Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Ivacaftor

[4] U.S. Patent 10,676,472 B2. (2020). Methods of preparing elexacaftor. Vertex Pharmaceuticals Incorporated.

[5] U.S. Patent 9,573,910 B2. (2017). Compounds and methods for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated.

[6] U.S. Patent 7,943,618 B2. (2011). Compounds and methods for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated.